Advancing Curative Therapies for Autoimmune Diseases
Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases.
Agenda highlights include:
- Standardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy
- Delving into antigen selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease, Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, IBD, and more
- Advancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond
Join your colleagues and thought leaders in February to take actionable insights back to your team at the industry’s only, dedicated, antigen-specific immune tolerance meeting. Join Eli Lilly, AbbVie, Pfizer, Diamyd, Moderna, Toleranzia, GRO Bio and more.
Find out more here: https://ter.li/ujeia4